Tags

Type your tag names separated by a space and hit enter

A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence.
J Psychopharmacol. 2011 Feb; 25(2):254-62.JP

Abstract

Drug use has been associated with craving, which may be described as a powerful and sometimes overwhelming urge to use the drug. Patients seeking treatment for methylamphetamine dependence must cope with drug cravings as they engage in psychosocial treatments. Changes in brain GABA(A) receptors during substance use and withdrawal provide a neurobiological basis for craving and associated anxiety. Flumazenil (a benzodiazepine antagonist) plus gabapentin (an antiepileptic) were compared with placebo in a randomized, double-blind study to assess the effects on craving during initial treatment for methylamphetamine dependence. Evaluation was conducted over a 30-day period. Craving and drug use were found to be highly correlated. Craving was reduced significantly in the flumazenil plus gabapentin group compared with placebo following the initial treatment period and throughout the 30 days. Decreased methylamphetamine use was also observed, as measured by urine drug screens and self-reports.

Authors+Show Affiliations

Research Across America, CNS Research Group, Dallas, TX, USA. urschel@recovery-science.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19939864

Citation

Urschel, Harold C., et al. "A Controlled Trial of Flumazenil and Gabapentin for Initial Treatment of Methylamphetamine Dependence." Journal of Psychopharmacology (Oxford, England), vol. 25, no. 2, 2011, pp. 254-62.
Urschel HC, Hanselka LL, Baron M. A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence. J Psychopharmacol. 2011;25(2):254-62.
Urschel, H. C., Hanselka, L. L., & Baron, M. (2011). A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence. Journal of Psychopharmacology (Oxford, England), 25(2), 254-62. https://doi.org/10.1177/0269881109349837
Urschel HC, Hanselka LL, Baron M. A Controlled Trial of Flumazenil and Gabapentin for Initial Treatment of Methylamphetamine Dependence. J Psychopharmacol. 2011;25(2):254-62. PubMed PMID: 19939864.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence. AU - Urschel,Harold C,3rd AU - Hanselka,Larry L, AU - Baron,Michael, Y1 - 2009/11/25/ PY - 2009/11/27/entrez PY - 2009/11/27/pubmed PY - 2011/5/12/medline SP - 254 EP - 62 JF - Journal of psychopharmacology (Oxford, England) JO - J Psychopharmacol VL - 25 IS - 2 N2 - Drug use has been associated with craving, which may be described as a powerful and sometimes overwhelming urge to use the drug. Patients seeking treatment for methylamphetamine dependence must cope with drug cravings as they engage in psychosocial treatments. Changes in brain GABA(A) receptors during substance use and withdrawal provide a neurobiological basis for craving and associated anxiety. Flumazenil (a benzodiazepine antagonist) plus gabapentin (an antiepileptic) were compared with placebo in a randomized, double-blind study to assess the effects on craving during initial treatment for methylamphetamine dependence. Evaluation was conducted over a 30-day period. Craving and drug use were found to be highly correlated. Craving was reduced significantly in the flumazenil plus gabapentin group compared with placebo following the initial treatment period and throughout the 30 days. Decreased methylamphetamine use was also observed, as measured by urine drug screens and self-reports. SN - 1461-7285 UR - https://www.unboundmedicine.com/medline/citation/19939864/A_controlled_trial_of_flumazenil_and_gabapentin_for_initial_treatment_of_methylamphetamine_dependence_ L2 - https://journals.sagepub.com/doi/10.1177/0269881109349837?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -